Waters Co. (NYSE:WAT) has been given a consensus recommendation of “Hold” by the nineteen research firms that are currently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, twelve have issued a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $203.62.

A number of research analysts recently weighed in on the company. Zacks Investment Research raised Waters from a “sell” rating to a “hold” rating in a research note on Thursday. Robert W. Baird upped their price target on Waters from $201.00 to $212.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 25th. Morgan Stanley dropped their price target on Waters from $205.00 to $204.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 25th. Janney Montgomery Scott downgraded Waters from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $230.00 to $211.00 in a research note on Tuesday, July 17th. Finally, Bank of America downgraded Waters from a “neutral” rating to an “underperform” rating and set a $190.00 price target on the stock. in a research note on Monday, July 16th.

Shares of NYSE:WAT opened at $189.36 on Friday. The stock has a market capitalization of $14.44 billion, a PE ratio of 25.28, a price-to-earnings-growth ratio of 2.29 and a beta of 0.98. The company has a debt-to-equity ratio of 0.58, a quick ratio of 5.95 and a current ratio of 6.58. Waters has a 1 year low of $177.58 and a 1 year high of $220.20.

Waters (NYSE:WAT) last posted its quarterly earnings results on Tuesday, July 24th. The medical instruments supplier reported $1.95 earnings per share for the quarter, topping analysts’ consensus estimates of $1.92 by $0.03. Waters had a return on equity of 27.85% and a net margin of 2.12%. The business had revenue of $596.20 million for the quarter, compared to the consensus estimate of $598.73 million. During the same period in the prior year, the business earned $1.76 EPS. The firm’s revenue for the quarter was up 6.8% on a year-over-year basis. equities research analysts forecast that Waters will post 8.12 EPS for the current fiscal year.

In other Waters news, SVP Michael C. Harrington sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, June 1st. The stock was sold at an average price of $194.64, for a total transaction of $2,919,600.00. Following the completion of the sale, the senior vice president now directly owns 17,037 shares of the company’s stock, valued at approximately $3,316,081.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.98% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. increased its holdings in Waters by 0.5% during the 1st quarter. BlackRock Inc. now owns 5,641,405 shares of the medical instruments supplier’s stock worth $1,120,666,000 after purchasing an additional 30,010 shares in the last quarter. Fundsmith LLP increased its holdings in Waters by 8.2% during the 2nd quarter. Fundsmith LLP now owns 4,728,994 shares of the medical instruments supplier’s stock worth $915,485,000 after purchasing an additional 360,404 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in Waters by 156.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 4,358,976 shares of the medical instruments supplier’s stock worth $843,852,000 after purchasing an additional 2,657,055 shares in the last quarter. Jensen Investment Management Inc. increased its holdings in Waters by 5.3% during the 2nd quarter. Jensen Investment Management Inc. now owns 1,057,151 shares of the medical instruments supplier’s stock worth $204,654,000 after purchasing an additional 52,840 shares in the last quarter. Finally, Bessemer Group Inc. increased its holdings in Waters by 1.1% during the 2nd quarter. Bessemer Group Inc. now owns 656,302 shares of the medical instruments supplier’s stock worth $127,054,000 after purchasing an additional 6,880 shares in the last quarter. 96.43% of the stock is owned by hedge funds and other institutional investors.

Waters Company Profile

Waters Corporation, a specialty measurement company, provides analytical workflow solutions in the United States, Europe, Asia, and internationally. It designs, manufactures, sells, and services high and ultra performance liquid chromatography technology, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.

See Also: Stock Symbols and CUSIP Explained

Analyst Recommendations for Waters (NYSE:WAT)

Receive News & Ratings for Waters Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters and related companies with MarketBeat.com's FREE daily email newsletter.